TFF Pharmaceuticals Inc
NASDAQ:TFFP
TFF Pharmaceuticals Inc
TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. The company is headquartered in Austin, Texas. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing drug products based on its Thin Film Freezing (TFF) technology platform. Its TFF platform is designed to enable solubility of poorly water-soluble drugs. Its drug candidates include TFF Voriconazole Inhalation Powder (VIP), TFF Tacrolimus Inhalation Powder (TIP) and Triple Combination. The company is developing TFF VIP to treat invasive pulmonary aspergillosis (IPA), a severe fungal pulmonary disease. TFF VIP is being developed as an inhaled dry powder drug. The company is developing TFF TIP, a dry powder version of Tacrolimus, an immunosuppressive drug used in transplant medicine. The company is developing Triple Combination, a dry powder drug combination to treat chronic obstructive pulmonary disease (COPD) and asthma. Its other dry powder products include Inhaled SARS-CoV2 Monoclonal Antibody, Niclosamide Inhalation Powder, Cannabidiol (CBD) and Vaccines.
TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. The company is headquartered in Austin, Texas. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing drug products based on its Thin Film Freezing (TFF) technology platform. Its TFF platform is designed to enable solubility of poorly water-soluble drugs. Its drug candidates include TFF Voriconazole Inhalation Powder (VIP), TFF Tacrolimus Inhalation Powder (TIP) and Triple Combination. The company is developing TFF VIP to treat invasive pulmonary aspergillosis (IPA), a severe fungal pulmonary disease. TFF VIP is being developed as an inhaled dry powder drug. The company is developing TFF TIP, a dry powder version of Tacrolimus, an immunosuppressive drug used in transplant medicine. The company is developing Triple Combination, a dry powder drug combination to treat chronic obstructive pulmonary disease (COPD) and asthma. Its other dry powder products include Inhaled SARS-CoV2 Monoclonal Antibody, Niclosamide Inhalation Powder, Cannabidiol (CBD) and Vaccines.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
